MELANOMA

This early-stage study is testing whether a personalized cancer vaccine, made from a patient's own tumor, can be safely combined with other immune-boosting drugs to treat melanoma. The goal is to see if this combination helps the body's immune system better recognize and attack c…

This early-phase study is testing the safety of combining a new cancer vaccine with an existing immunotherapy drug (pembrolizumab) in patients with advanced solid tumors that have spread and stopped responding to standard treatments. The vaccine is designed to train the immune sy…

This study is testing whether adding a personalized mRNA vaccine (V940) to a standard immunotherapy drug (pembrolizumab) is better at preventing melanoma from coming back after surgery than the drug alone. It involves about 1,089 people with high-risk melanoma who have had their …

This study is testing if a blood test that looks for tiny pieces of cancer DNA can help doctors decide when it might be safe for patients to stop their immunotherapy. It involves 39 people with advanced melanoma or non-small cell lung cancer whose cancer is under control after at…

This study tested whether a drug called pembrolizumab could prevent melanoma from coming back after surgery in high-risk patients. Over 1,000 participants who had their melanoma surgically removed were randomly assigned to receive either the drug or a placebo. The main goal was t…

This early-stage trial is testing a new drug called INBRX-106, both by itself and combined with an existing immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how …

This study is testing if giving two targeted drugs (dabrafenib and trametinib) for 12 weeks before surgery can shrink melanoma tumors that have spread to the lymph nodes. It involves 35 adults with a specific genetic mutation (BRAF V600). The main goal is to see if this pre-surge…

This study aims to see if a new, proposed biosimilar drug called GME751 works similarly to the established drug Keytruda (pembrolizumab). It involves 322 adults with stage II or III melanoma who have had their cancer surgically removed. The goal is to prevent the cancer from retu…

This study is testing a personalized approach to prevent melanoma skin cancer from coming back after surgery. Patients first get one dose of a drug (nivolumab) before their operation. Based on how the tumor responds to that single dose, doctors then assign a specific year-long dr…

This study is testing a personalized treatment for people with metastatic melanoma, a serious form of skin cancer that has spread. Doctors take a patient's own immune cells, grow them in large numbers in a lab, and then infuse them back into the patient to attack the cancer. The …

This study is testing a new oral drug, ARRY-614, to see if it can make standard immunotherapy drugs (nivolumab and ipilimumab) work better for people with advanced cancers. The first part checks the safety and best dose. The second part will see how well the combinations work to …

This study is testing if adding two oral drugs (encorafenib and binimetinib) to a standard immunotherapy (pembrolizumab) works better for people with advanced melanoma that has a specific BRAF gene mutation and hasn't been treated before. About 257 participants will be randomly a…

This study is testing whether a new two-drug immunotherapy combination works better than the current standard single-drug treatment for patients with high-risk melanoma that can be surgically removed. About 151 participants will receive the drugs before their surgery, and can con…

This early-stage study is testing a new proton radiation technique called Pro-GRID for patients with large, difficult-to-treat tumors. The method delivers radiation in a grid pattern to try to shrink tumors while sparing healthy tissue. Researchers aim to see if this approach is …

This study is testing whether a combination of two immunotherapy drugs, nivolumab and ipilimumab, can help prevent melanoma from returning in patients who have had it surgically removed but are at high risk of it coming back. The treatment is given for six months after surgery. T…

This study is testing whether a new two-drug combination (relatlimab plus nivolumab) is more effective at controlling advanced melanoma than the standard single drug (nivolumab). It involves over 700 adults with previously untreated melanoma that has spread or cannot be surgicall…

This early-stage study is testing a new drug called belvarafenib, both by itself and in combination with other cancer drugs, for people with advanced melanoma that has a specific genetic change (NRAS mutation) and has stopped responding to standard immunotherapy. The main goals a…

This study is testing whether adding two experimental vaccines (IO102/IO103) to standard immunotherapy drugs (nivolumab and relatlimab) is safe and effective for people with advanced melanoma that can't be surgically removed. The trial involves 43 adults who haven't received any …

This study is testing a new combination of two drugs, cobolimab and dostarlimab, for children and young adults with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest and most effective dose and to see how well the body tolera…

This early-stage trial is testing the safety of a new treatment called ADP-A2M4CD8, which uses a patient's own modified immune cells to fight cancer. The study will enroll 120 adults with one of nine advanced cancers who have specific genetic markers. Researchers will give the ce…

This study is testing whether adding a drug called cabozantinib to two existing immunotherapy drugs (nivolumab and ipilimumab) can better control advanced melanoma that cannot be removed by surgery. The main goal is to see if this combination helps patients live longer without th…

This study compares two drugs, infliximab and vedolizumab, to treat severe colon inflammation and diarrhea caused by cancer immunotherapy drugs. The trial involves 47 patients with melanoma, lung cancer, or urinary cancers who developed these side effects. Researchers aim to find…

This study is testing a new combination of immune-boosting drugs for people with advanced cancers whose disease has progressed after treatment with standard immunotherapies like pembrolizumab or nivolumab. It aims to see if adding a drug called NAI to other treatments can help sh…

This study is testing whether giving two immunotherapy drugs (nivolumab and ipilimumab) before surgery can shrink melanoma tumors and prevent the cancer from coming back. It involves 28 adults with stage III melanoma that can be surgically removed. The research also explores a ne…

This early-stage study is testing the safety of a new cancer drug called PF-08046032, both by itself and combined with another drug called sasanlimab. It involves a small group of adults with advanced or spreading cancers, including certain lymphomas and solid tumors like lung ca…

This study aims to find the best way to give high-dose radiation to control cancer that has spread to bones, the spine, soft tissue, or lymph nodes. It compares giving all the radiation in one day versus spreading it over three days, using precise imaging to target the tumor and …

This study is testing whether adding a drug called tocilizumab to two existing immunotherapy drugs (ipilimumab and nivolumab) is safe and effective for people with advanced melanoma that cannot be removed by surgery. The trial involves 71 participants and will measure side effect…

This study is testing whether the drug ensartinib can help control advanced melanoma that has specific genetic changes in the ALK gene. The trial is for patients whose cancer has continued to grow despite standard treatments like immunotherapy. Researchers want to see if this tar…

This is an early-stage study to find a safe dose of a new immunotherapy drug called HFB200301. It is being tested alone and in combination with an existing drug (tislelizumab) in adults with advanced solid tumors who have already tried other treatments. The main goal is to see ho…

This early-stage study aims to find the highest safe dose of a new drug called XL888 when given with two existing melanoma drugs (vemurafenib and cobimetinib). It involves 26 adults with advanced, BRAF-mutated melanoma that cannot be removed by surgery. The main goals are to dete…

This study is testing a drug called entrectinib for people with advanced solid tumors that have specific genetic changes (NTRK, ROS1, or ALK gene rearrangements). It's a 'basket trial,' meaning it groups patients by their tumor's genetic type rather than where the cancer started …

This program provided access to two targeted drugs, trametinib and dabrafenib, for adults with advanced, BRAF mutation-positive melanoma who had no other treatment options available. It was a compassionate use program, meaning it offered the drugs outside of regular clinical tria…

This study is testing whether adding a personalized cancer vaccine to standard immunotherapy helps prevent melanoma from returning after surgery. It involves 267 people with high-risk melanoma who have had their cancer completely removed. The goal is to see if the combination tre…

This is the first human study testing a new cancer drug called AB248, either alone or combined with an existing immunotherapy (pembrolizumab). The trial aims to find safe doses and see if the treatment shows early signs of helping adults with advanced solid tumors that have sprea…

This early-stage trial is testing whether adding an experimental oral drug called AZD6244 to standard chemotherapy is safe for people with advanced cancers like breast, lung, colon, and kidney cancer. The study will find the highest dose patients can tolerate and track how the bo…

This is an early-stage study testing a new drug called DKY709, both alone and combined with another drug (PDR001), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find safe doses and understand side effects. Researcher…

This early-stage study is testing a new oral drug called KIN-2787 in adults with advanced solid tumors that have specific BRAF or NRAS gene mutations, including lung cancer and melanoma. The main goals are to find a safe dose, see how the body processes the drug, and get an early…

This early-stage study is testing a new type of personalized cell therapy for children and young adults whose solid tumors have come back or haven't responded to other treatments. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cance…

This is a first-in-human study testing a new personalized cell therapy for people with advanced solid tumors that have not responded to standard treatments. Doctors take a patient's own tumor-fighting immune cells from a tumor sample, grow large numbers of the most potent ones in…

This is an early-stage study to find a safe dose of a new immunotherapy drug called HFB200603. It will be tested alone and in combination with an existing drug, tislelizumab, in 83 adults with advanced solid tumors like lung, kidney, or skin cancer. The main goal is to check for …

This study is testing whether two immunotherapy drugs, nivolumab alone or nivolumab combined with ipilimumab, can help control melanoma that has spread to the brain. It enrolled 76 adults with these brain metastases. The goal is to see if these drugs, which help the immune system…

This early-stage trial is testing whether adding a specific mix of gut bacteria (MB097) to a standard immunotherapy drug (pembrolizumab) can help patients with advanced melanoma whose cancer has stopped responding to similar treatments. The main goal is to see if this combination…

This is a first-in-human study to test the safety and find the right dose of a new, personalized cell therapy called OBX-115, given with the drug acetazolamide. It is for adults whose metastatic melanoma has come back or stopped responding to standard immunotherapy. Researchers w…

This early-stage trial is testing a new antibody drug called GEN1042 to see if it's safe and can help control advanced solid tumors. Researchers are giving GEN1042 alone or combined with another cancer drug (pembrolizumab) to about 350 adults with cancers like lung, colorectal, m…

This early-stage study is testing a new personalized cell therapy called KSQ-001EX in people with advanced melanoma, lung cancer, or head and neck cancer. Doctors take a patient's own immune cells from a tumor, genetically modify them to potentially be more powerful, and then inf…

This early-phase trial is testing whether adding a new oral drug called dapansutrile can help restart the effectiveness of a standard immunotherapy (pembrolizumab) in patients with advanced melanoma. The study aims to find a safe dose and see if the combination can shrink tumors …

This study is observing whether a combination of two drugs, dabrafenib and trametinib, can help prevent melanoma skin cancer from returning in Chinese patients who have had it surgically removed. The treatment is given for one year to patients whose cancer has a specific genetic …

This large national trial is testing whether choosing cancer drugs based on the specific genetic changes found in a patient's tumor is more effective than standard approaches. It is for adults with advanced solid tumors, lymphoma, or multiple myeloma that have progressed after at…

This early-stage trial is testing a new three-drug combination for people with advanced melanoma that has spread or cannot be removed by surgery and has worsened after standard immunotherapy. The study aims to find a safe and effective dose of the experimental drug BI-1607 when g…

This large, late-stage trial is comparing a new two-drug combination (fianlimab + cemiplimab) against the current standard treatment (pembrolizumab) for people with advanced melanoma that cannot be removed by surgery. The main goal is to see if the new combination helps patients …

This study is testing several combinations of an experimental drug called LXH254 with other cancer medications for people with advanced melanoma that has spread and hasn't responded to previous treatments. The research aims to see if these combinations can shrink tumors and contr…

This early-stage trial is testing the safety and finding the right dose of a two-drug combination (naptumomab estafenatox and durvalumab) for people with advanced or metastatic solid tumors. It will enroll about 120 adults with one of many eligible cancer types, including breast,…

This study is testing if a new drug called ABP 206 works as well as the standard treatment (nivolumab) for people with advanced melanoma that cannot be removed by surgery. It involves 633 adults who have not yet received any treatment for their advanced cancer. The goal is to see…

This early-to-mid stage trial is testing whether a new two-drug combination can help control advanced bladder, kidney, or skin cancers. The study is for people whose cancer has spread or returned after trying at least one other treatment. Researchers want to see if the drugs, whi…

This early-stage study is testing the safety of a new, personalized cell therapy for people with advanced solid tumors that have stopped responding to standard treatments. Doctors collect a patient's own immune cells, genetically modify them to better recognize and attack their s…

This early-stage study tests a personalized cell therapy for people with advanced solid tumors. Doctors collect a patient's own immune cells, genetically modify them in a lab to better recognize and attack cancer, then infuse them back into the patient. The main goals are to chec…

This is an early-stage study to find the safest dose of a new drug, MGN1703, when given with an existing immunotherapy drug, ipilimumab. It involves about 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to see how much of th…

This early safety study aims to find the right dose and understand the side effects of a new drug combination for people with advanced solid tumors who also have liver or kidney problems. It tests adding a pill called veliparib to standard chemotherapy drugs. The main goal is to …

This study is testing a new type of PET/CT scanner called uEXPLORER to see if it can produce images as good as standard scanners, but in less time. It involves 180 adults with lung cancer, lymphoma, or melanoma who are already scheduled for a standard PET/CT scan. The main goal i…

This study is testing a new imaging method called MSOT to see if it can help doctors better visualize breast tumors and melanoma. Participants will have the MSOT scan right before their standard breast biopsy procedure. The goal is to see if this new technology can successfully c…

This study is tracking the long-term health of 48 people with advanced skin cancer (melanoma) who previously received an experimental two-drug combination. No new treatment is given during this follow-up phase. Researchers are monitoring cancer status, overall health, and any add…

This study aims to understand how two new experimental drugs travel to and gather in tumors in people with advanced head and neck cancer, lung cancer, or melanoma. Participants receive one of the new drugs along with an existing immunotherapy, and doctors use special PET scans to…

This study is testing whether analyzing tumor DNA found in blood can help doctors predict when melanoma treatments might stop working. It involves 136 patients with stage IIB-IV melanoma who have had surgery and are receiving standard follow-up treatments. Researchers will track …

This study aims to collect leftover tissue and blood samples from people with cancer who are already having surgery or a biopsy. Researchers will study these samples to better understand cancer and find new targets for future treatments. The study will enroll about 1200 adults an…

This study aims to understand how advanced cancers like melanoma and head/neck cancer change and evolve when treated with immunotherapy drugs. Researchers will collect tumor biopsies and blood samples from a small group of patients at different points during their treatment. The …

This study is looking back at the medical records of children in the Netherlands who were treated for advanced melanoma with a drug called ipilimumab. The goal is to understand the long-term side effects, survival rates, and overall health outcomes for these young patients. It is…

This study aimed to understand how community cancer clinics test for biomarkers—specific genetic changes in tumors—to help guide treatment decisions for common cancers like breast, lung, and colorectal. It planned to survey pathology labs to see what tests they run, how quickly t…

This study collects leftover tissue and blood samples from patients with various cancers to help researchers understand these diseases better. The samples come from patients already having medical procedures, using only material that would otherwise be discarded. Researchers will…

This study looks back at medical records to understand how well immunotherapy cancer drugs work for American Indian patients compared to White patients. Researchers will analyze survival times, side effects, and cancer-related deaths in 72 patients who were treated between 2015 a…

This study aims to understand whether exposure to farm environments during childhood increases the risk of developing cancer and other diseases in adulthood. Researchers are following over 64,000 adults who grew up on farms, collecting health information and biological samples ov…

This study aims to understand if changing diet and exercise habits affects gut bacteria in people with melanoma who are receiving immunotherapy treatment. Researchers want to see if a plant-based, high-fiber diet combined with regular exercise increases gut bacteria diversity and…

This study follows patients for up to 15 years after they received experimental gene therapies for cancers like melanoma and neuroendocrine tumors. The goal is to monitor long-term safety and health outcomes, as required by the FDA. Participants will have regular check-ups, blood…

This study aims to understand how a lab-made antibody called Hu3F8 moves through the body and reaches tumors in patients with certain advanced cancers. Researchers will use a special PET scan to track a tiny radioactive tag attached to the antibody. The goal is to gather informat…

This study collects blood and tumor cells from cancer patients and blood from healthy volunteers. The cells are used in the lab to support research into future immune cell therapies for cancers like melanoma, breast cancer, and lung cancer. No treatment is given in this study; it…